← Back to Clinical Trials
Recruiting NCT06422052

NCT06422052 Epidemiological Investigation of Helicobacter Pylori-infected Patients and the Effect of Eradication Treatment on Dyspepsia Symptoms

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06422052
Status Recruiting
Phase
Sponsor Shanghai Jiao Tong University School of Medicine
Condition Helicobacter Pylori Infection
Study Type OBSERVATIONAL
Enrollment 2,242 participants
Start Date 2024-03-11
Primary Completion 2025-05-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL
Interventions
Epidemiological questionnaire and Functional Dyspepsia Symptom Diary(FDSD)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,242 participants in total. It began in 2024-03-11 with a primary completion date of 2025-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objectives of this multicenter, prospective, observational study were to investigate the incidence of dyspeptic symptoms in patients with Helicobacter pylori (H. pylori) infection and to continuously follow up the remission of dyspeptic symptoms after H. pylori eradication, so as to provide reference for the clinical diagnosis and treatment strategies of patients with H. pylori infection and dyspeptic symptoms.

Eligibility Criteria

Inclusion Criteria: * Male or female patients aged 18-80 years * H. pylori infection diagnosed by 13C/ 14C-UBT (\> 2 times the cutoff value) and/or gastroscopy (rapid urease strong positive and histological positive) * Treatment-naive patients with Helicobacter pylori * Ability and willingness to participate in the study and to sign and give informed consent Exclusion Criteria: * Under 18 or over 80 years old * Organic digestive diseases, such as active peptic ulcer, gastroesophageal reflux, gastrointestinal bleeding, acute/chronic pancreatitis, acute/chronic cholecystitis, gallstones, intestinal obstruction, inflammatory bowel disease, etc. * Combined with melena, hematemesis, anemia, emaciation and other alarm symptoms * Pregnant and lactating women * History of cancer * History of subtotal gastrectomy * Severe organ dysfunction of heart, liver, kidney, lung and other important organs and congenital diseases, such as grade IV heart failure, liver failure, uremia, respiratory failure, hemophilia, Wilson's disease, etc.

Contact & Investigator

Central Contact

Hong Lu, MD

✉ hlu@sjtu.edu.cn

📞 +8613611958022

Frequently Asked Questions

Who can join the NCT06422052 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Helicobacter Pylori Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06422052 currently recruiting?

Yes, NCT06422052 is actively recruiting participants. Contact the research team at hlu@sjtu.edu.cn for enrollment information.

Where is the NCT06422052 trial being conducted?

This trial is being conducted at Chongqing, China, Chongqing, China, Chongqing, China, Xiamen, China and 11 additional locations.

Who is sponsoring the NCT06422052 clinical trial?

NCT06422052 is sponsored by Shanghai Jiao Tong University School of Medicine. The trial plans to enroll 2,242 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology